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Short Research Communication
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We undertook a qualitative e-mail survey of federally-funded principal investigators of their views of the US
human subjects protection system, intended to identify the range of investigator attitudes. This was an
exploratory study with a 14% response rate. Twenty-eight principal investigators responded; their comments
were analyzed to show underlying themes, which are here presented along with supporting quotations.
There was consensus that it is important to protect human subjects from research abuse, but disagreement over
how well the IRB system is functioning. Some researchers felt that the system is effective and serves its purpose
well. Of those who support the system, some endorse its methods, purpose, and daily functioning, as they
experience it, without reservation. Others, while expressing some frustration, feel that the purpose is important
and their local IRB does its best to make a difficult system work well.
Those investigators who were more harshly critical commented on multiple flaws in the system, including (1)
consent forms that are inappropriate and incomprehensible, (2) an emphasis on minutiae, and (3) concern with
protecting the institution more than research subjects. Respondents told us that the IRB system is a particular
burden for research in neurology, emergency medical conditions, repositories, and social sciences in general; a
more comprehensive study might identify other problematic areas. Significant concern was expressed about the
cost, inefficiency, and irrationality of IRB review. The IRB system works well for some researchers, but our results
indicate that other investigators feel the costs outweigh the benefits.
Key words: Ethics Committees, Research, Questionnaires, Attitude

INTRODUCTION
The human subjects protection system is
ever-enlarging yet its quality and efficiency are cast in
doubt by experts, [1] review bodies, [2] and field- or
discipline-specific committees. [3] In a complex system
with multiple stakeholders, one important source of
insight is with those who are regulated—the principal
investigators. The views of investigators are therefore
important in understanding the system as it functions
today.
Previous work suggests that the opinions of
investigators toward the IRB system are mixed. An
informal survey of members of several social science
organizations conducted in 2000 drew mixed results.
Some of the researchers who were polled reported
excellent rapport with their local IRBs; others were
frustrated by a system that delayed and obstructed
their research. [3] Borris and Moss studied the views of

a group consisting primarily of federally-funded
principal investigators; they identified significant
problems with the system. [4] Investigators whose
research requires data collection in more than one
location have been especially vocal about the
shortcomings of the IRB system. [5-7]
We undertook a study of researchers’ attitudes
toward the IRB system, using a confidential e-mail
questionnaire format to encourage candid responses.
We limited our sample to investigators with current
NIH funding in human subjects research. We
recognized that this unfunded work could not attempt
to paint a comprehensive picture of researchers’
attitudes and experiences; our more modest goal was
exploratory, to gather the range of attitudes from a
small sample of people with in-depth knowledge of
the system.
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METHODS
Surveys were sent via e-mail in two phases in
2003, using NIH-funded principal investigators listed
in the CRISP database whose project abstracts
indicated that they used human subjects. The pilot
phase used a single e-mail solicitation only, including a
six item questionnaire. This was sent to 34
investigators; four had invalid e-mail addresses, and
two responses were received, for a response rate of 7%.
The second phase survey was sent to 193 investigators
who were NIH-funded to do research in human
subjects in 2003. This phase included an e-mail alerting
potential subjects to the study, an e-mail containing the
survey, and two follow-ups for those who did not
respond to the initial solicitation. Thirteen of our
subjects did not have valid e-mail addresses; of the
remaining 180, valid responses were received from 26.
We combined respondents from the first and second
phases, giving us a final sample size of 28, which is
adequate for the purposes of qualitative analysis.
Because this was an exploratory study, we asked
open-ended questions and analyzed the responses
qualitatively. The project was approved by the Baylor
College of Medicine Institutional Review Board.
The final survey included these items:
1. What has been your experience with the human
subjects protection system in general? What do you
like? What would you change?
2. What has been your experience with the
informed consent process with potential subjects? Is
there anything you would change?
3. Do you feel your IRB does its job well? If so,
what helps you the most? If not, how could it improve?
4. Do you feel that your IRB usually understands
your protocols adequately?
5. Have you ever served on an IRB?
6. What other thoughts do you have on informed
consent and the human subjects protection system?

RESULTS
I. Positive comments
A. Toward the system
Some respondents emphasized their conviction
that the human subjects protection system is an
essential safeguard in clinical research. Respondents
identified several significant benefits of the overall
system, including its function as a safeguard against
overoptimistic investigators (subject 6), protecting
subjects against both nonphysical and physical harms
(subject 6), the promotion of “social justice” (subject 6),
and the provision of online ethics training by the NIH
(subject 22).
I think that the informed consent process is an
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essential element of both research and treatment.
Risks occur in many situations that are not
commonly perceived as such and individuals
deserve protection. (subject 6)
Another respondent noted that self-interest is
also a motivation:
My experience has been good to excellent
overall. The time I have to spend on consent
forms and IRB approval is bothersome at times
but I gladly do it knowing that this system
protects every researcher. I don't want my
research shut down because some other
researcher was sloppy and a subject was harmed.
The IRB system is the only protection I have
against that. (subject 15)

B. Toward individual IRBs
Individual IRBs were lauded for taking their
work seriously (subjects 6, 13, 18, 20, and 23), for being
sensible (subject 24), and for having a service
orientation, including frequent meetings (subject 8),
prompt responses (subject 6), bringing in outside
expertise when appropriate (subject 6), and providing
individual help and feedback (subjects 8, 11, 14, 15,
and 16). Some respondents praised their IRB for
excellence in helping researchers within a set of
constraints that are challenging:
[Our] IRB has been good to work with, and I
don't have the same horror stories that I've heard
from others. They labor under the same
antedeluvian mindset that has been imposed on
everyone, but have accommodated to it in a way
that is helpful to researchers in general. Most
important, our IRB has avoided the pitfall of
rewriting protocols (subject 8).

II. Negative comments
A. The system as a whole
Not all of our subjects felt that the human
subjects protection system works adequately.
Overall, I find the people working in IRB offices
to be trying very hard to keep a sane approach in
what is rapidly deteriorating into an very insane
process.
The
constraints
placed
upon
investigators and indeed research subjects by
OHPR and so-called ethicists approaches the
absurd. I am both a PI and have participated in
clinical trials [as a subject]. Getting protocols
approved gets worse each year because you have
to document more and more and more USELESS
stuff. For most of my work I receive coded
samples devoid of patient identifiers, yet I have
to fill in all sorts of crap and REPEAT OVER
AND OVER AND OVER AGAIN that I couldn't
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track down these subjects if i tried. Examples of
this absurdity include: mandating IRB approval
for a collaborator to look at the viral sequences
from patients samples that were devoid of all
identifiers. He may be good but I doubt he could
look at someone and figure out who they were
by the sequence of their virus. (subject 27)

B. Consent forms
Informed consent, by which our subjects mean
the consent forms that are the focus of much IRB effort,
was treated with widespread derision, with 15 out of
28 of our subjects providing criticisms such as
“unlikely to be read,” or “incomprehensible.” (subjects
1, 4, 8, 10, 11, 12, 14, 15, 16, 17, 24, 25, 26, 27, 28)
Excessive length and detail were commonly cited,
resulting in reduced understanding (subject 11) and
potentially reduced enrollment. (subjects 14, 15, 16, 17)
Researchers were troubled by requirements to mention
the risk of death even in minimal risk procedures
(subjects 4, 17, 25) and felt that inappropriate language,
such as a paragraph on the risk of death in a minimal
risk procedure, was inflammatory and unduly
frightening. (subjects 4, 17, 25)
Most informed consents include FAR TOO
MUCH INFORMATION and the average person
doesn't understand what is in them. They don't
inform, at best they bore and confuse. Informed
consents have become "legal" documents to
protect the institutions from OHPR and have
little to do with informing subjects let alone
protecting them. (subject 27)
C. IRBs
IRBs were often portrayed as slow or
cumbersome. (subjects 1, 4, 7, 12, 14, 16, 28) Caution
was reflected in the refusal of a Department of Health
IRB that refused to approve smoking-related research
because it was “too politically hot.” IRBs were seen by
some as not competent in the area under review
(subject 4), not understanding the protocols (subject 4)
or the analytic methods (subject 27) submitted.
Some IRBs were seen as applying federal
regulations and their own local custom in arbitrary
and even irrational ways. One IRB required that the
informed consent form be written at the sixth grade
reading level even when the subjects are college
students. (subject 19) Another respondent commented,
I believe that most subjects skim through the
incredibly long informed consents, believing that
most of it is simply bureaucracy. They often are
most puzzled by statements such as denial that
an institution will pay for medical costs if they
are injured in a study, when their participation
simply includes filling out questionnaires.
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(subject 10)
Two respondents spontaneously mentioned fear
of IRBs.
There is…quite some show of 'muscle' and if a
member has a score to settle with an investigator,
woe to the whole study. I have seen when
investigators are frustrated but they dare not
speak out lest the committees sit on their studies
for ever (with a what-can-you-do attitude). You
should see they way the letters to IRBs are full
of 'pleading' words, and this is characteristic of
both the local and the US IRBs I have had the
misfortune of working with in other studies!
(subject 28)
A final comment: All of our emails may be
monitored, and although I have nothing to say
that I would not share with any official of [my
institution], and email is convenient, I wonder if
this is the wisest way to conduct this survey?
(subject 10)

D. Protection . . . for whom
Seven subjects, one quarter of our sample,
commented that IRBs do not seem to have protecting
subjects as their highest priority. (subjects 8, 9, 10, 12,
14, 27, 28)
Many IRB members are out more to protect
themselves (from possible future lawsuits) than
the hullabaloo about protecting study subjects.
Many make decisions that harm clients in the
long run without caring at all, as long as THEY
feel safe. (subject 28)
Informed consent has clearly transmogrified
from protection of subjects to protection of the
institution. We are required to use language that
is incomprehensible to most research subjects (I
do street based work in STD/HIV and many of
our clients are not fluent readers, so the problem
is greater for me and my colleagues). This
absurdity has recently been compounded by
HIPAA, and the extra pages that clients must
now wade through. In short, the informed
consent process has become a travesty. (subject
8)
E. Specific areas of research
The most impassioned comments were made by
investigators who believe that entire lines of research
are made difficult or impossible by the human subjects
protection system. (subjects 1, 9). Respondents
identified four specific lines of research that are so
burdened.
1. Neurology
A researcher who works in Neurology pointed to
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the difficulties posed by the human subjects protection
system and raised a corollary concern, that the system
discourages young researchers from entering careers
in human research:
If parents of children dying of some of the
diseases we encounter in neurology understood
how much more cumbersome and expensive
research is as the result of this system, the system
would be in big trouble. Even worse if they
realized how these problems conspire to dampen
enthusiasm of young people who might
otherwise have gone into clinical/translational
research. (subject 2)
2. Social science research
Three respondents commented that the system
(both the regulations and their application by
individual IRBs) seems to them to work badly for
social science research. (subjects 10, 11, 26) One
respondent, who had served as chair of an IRB,
commented:
What I would like to see changed is the federal
law/policy that was developed specifically for
biomedical research. It needs to be adapted for
social science research. . . . For instance, it makes
no sense to mention alternative procedures when
conducting a lab experiment or field survey. …
Some common sense could be applied to develop
an appropriate parallel set of guidelines to fit the
needs of social science. (subject 11)
3. Urgent or emergent medical conditions
Obtaining informed consent according to usual
standards was a particular problem in research in
emergency medical conditions (subjects 14, 16):
I am involved in acute stroke clinical trials, and
informed consent with a confused patient and
family in the ER under a very tight time limit is
very difficult. (subject 14)
4. Repository research
A repository or data bank is a collection of
medical information, tissue or blood samples, or other
information from many individuals.
The constraints on repository material are a
major set back in science and I hope all those at
OHPR and the ethicists die of diseases that we
could have made significant progress on if we
had these valuable research. USE OF THESE
SAMPLES IN NO CONCEIVABLE way harms
the study subjects. It is a bureaucratic legalistic
impediment to research that only HURTS people
and protects no one. (subject 27)
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F. A system under stress
Some of our subjects granted that it is essential to
protect human subjects yet questioned the viability of
the current system. One respondent, a former chair of
an IRB, commented:
We've reached a point . . . where the logic of
increasing improbability holds sway. If
something could happen, it might happen, or
perhaps it will happen, and we must defend
against it. The work of the IRB has become the
intellectual (jesuitical? talmudic?) exercise of
trying to see what could go wrong and taking
steps to prevent it, whatever the probability and
whatever the cost. This is the same logic that
drives airport security. To stave off an event with
nanoprobability but enormous potential impact,
we have to do everything to everybody, and
such an imperative has an inescapable logic. You
begin at Point A, and have logical justification
for each step along the way to Z, but the
situation you end up in, at Z, is ludicrous. . . . The
system is clearly in a downward spiral, as the . . .
addition of HIPAA requirements demonstrates.
This involution takes us deeper into a
bureaucratic morass, from which there is no
visible exit strategy at the moment. I think all of
us will just have to wait until it becomes
apparent that useful research on human subjects
cannot be performed, and there is a sea change in
the way we approach the issue of protecting
people from us. (subject 8)

DISCUSSION
All of our subjects explicitly or implicitly
recognized the importance of treating human subjects
appropriately. All of our subjects have worked with
the human subjects protection system, and forty
percent, including two respondents whose comments
were entirely negative, were present or former
members of IRBs.
Where investigators perceive problems, it is
important to distinguish flawed implementation of
regulations by the local IRB from problems inherent in
the IRB system or in the governing regulations
themselves. Some of our respondents complained,
perhaps appropriately; others were happy to point out
ways in which their IRB met its ethical obligations in a
timely, courteous, and efficient manner.
This was an exploratory study with a low
response rate, which imposes significant limits on the
conclusions we can draw. These data do not support
quantitative inferences. Our results show clearly that
researchers range from very satisfied to extremely
dissatisfied with the IRB system, but we cannot tell
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how these attitudes are distributed across the many
thousands of investigators doing human subject
research today.
Sometimes there is tension between protecting
human subjects and permitting research to go forward.
Our system correctly prohibits research that sacrifices
the interests of subjects even if society might benefit.
[8] Sometimes, however, the risks (to the individual)
and benefits (for society) are not easy to compare; this
is most apparent in our subjects’ discussions of
research in neurology, using repository material, in the
social sciences, and in emergency and neurological
medical conditions. We did not intend a
comprehensive study of the impact of the IRB system
on different areas of research, and did not inquire as to
the field of research of our respondents, learning this
information only when it was volunteered. We suspect
that a larger survey would have identified more areas
in which the IRB system causes severe difficulties, as
well as other research methodologies that are
particularly burdened (the problems with IRB review
of multicenter research are already well documented).
The current exception for research in emergencies
works, at least for subject 14, well enough to make
research in acute stroke possible, but still imposes a
substantial burden. In some circumstances, time spent
obtaining informed consent of any kind (for research
or for clinical treatment) directly reduces the time
available for prompt and effective intervention.
Social science is a particularly hard case. IRBs
work hard to protect the subjects of social science
research. It is, however, clear that some of the federal
regulations pertaining to research were not designed
to apply to social science research, and that some IRBs
do not understand this type of investigation.
The most important protection against abuse of
human subjects is the high ethical standard of
individual researchers. Some of our respondents
understand that protecting human subjects is more
than using an approved consent form. One respondent
commented that his experience with the human
subjects protection system has been “. . . positive but
cumbersome. I like going through the process of being
forced to think concretely about all possible ethical
dilemmas associated with a project in advance.”
(subject 4) This expresses nicely the attitude of a
conscientious investigator for whom the protection of
human subjects is an ideal. Many of our subjects feel
that the bureaucratic process now in place does little to
bring that ideal to reality.
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